ArticleBioorganic & medicinal chemistry letters2019
Muscarinic agonist, (±)-quinuclidin-3-yl-(4-fluorophenethyl)(phenyl)carbamate: High affinity, but low subtype selectivity for human M
Na-Ra Lee, Satheesh Gujarathi, Shobanbabu Bommagani, Kiranbabu Siripurapu, Guangrong Zheng, Linda P Dwoskin
Abstract read
In one paragraphArticle in Bioorganic & medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
6 authors.
Na-Ra LeeDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, United States.
Satheesh GujarathiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Shobanbabu BommaganiDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Kiranbabu SiripurapuDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, United States.
Guangrong ZhengDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, AR 72205, United States.
Linda P DwoskinDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, KY 40536, United States. Electronic address: ldwoskin@uky.edu.
Funding
Kentucky Center for Clinical and Translational ScienceUL1TR001998 · NCATS · UNIVERSITY OF KENTUCKY · PI HARTMANN, KATHERINE E, KERN, PHILIP A · 2016 to 2025
$34.2MDevelopment of M5 Selective Muscarinic AntagonistsR21DA030667 · NIDA · UNIV OF ARKANSAS FOR MED SCIS · PI ZHENG, GUANGRONG · 2011 to 2012
$408kNCATS NIH HHS UL1 TR001998NIDA NIH HHS R21 DA030667
6 · The paper itselfAbstract
Novel quinuclidinyl N-phenylcarbamate analogs were synthesized, and binding affinities at M
Indexed as
AnimalsCarbamatesCHO CellsCricetulusDose-Response Relationship, DrugHumansLigandsMolecular StructureMuscarinic AgonistsQuinuclidinesRatsReceptors, MuscarinicStructure-Activity RelationshipCarbamatesLigandsMuscarinic AgonistsQuinuclidinesReceptors, Muscarinic[(3)H]dopamine release[(3)H]N-methylscopolamine bindingCarbamateChronic obstructive pulmonary diseaseMuscarinic acetylcholine receptorsSubstance use disorders
Identifiers
PMID30554957
PMCPMC7160324
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390